Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H1 2017’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H1N1 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H1N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Beijing Minhai Biotechnology Co Ltd

CEL-SCI Corp

Cilian AG

Cocrystal Pharma Inc

ContraFect Corp

Curevac AG

EpiVax Inc

Etubics Corp

Gemmus Pharma Inc

Genentech Inc

iBio Inc

ILiAD Biotechnologies LLC

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Kyowa Hakko Kirin Co Ltd

Lakewood-Amedex Inc

Medicago Inc

MedImmune LLC

Microbiotix Inc

Mucosis BV

NanoViricides Inc

NewLink Genetics Corp

Novavax Inc

OPKO Health Inc

PeptiDream Inc

Prommune Inc

Protein Sciences Corp

Recce Ltd

Sanofi Pasteur SA

Sarepta Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Touchlight Genetics Ltd

Vaccibody AS

Vaxart Inc

Vironova AB

Visterra Inc

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Influenza A Virus, H1N1 Subtype Infections Overview 9

Influenza A Virus, H1N1 Subtype Infections Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 17

Products under Development by Universities/Institutes 22

Influenza A Virus, H1N1 Subtype Infections Therapeutics Assessment 23

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Influenza A Virus, H1N1 Subtype Infections Companies Involved in Therapeutics Development 31

AbbVie Inc 31

Akshaya Bio Inc 31

Altimmune Inc 32

Antigen Express Inc 32

Beijing Minhai Biotechnology Co Ltd 33

CEL-SCI Corp 33

Cilian AG 34

Cocrystal Pharma Inc 34

ContraFect Corp 35

Curevac AG 35

EpiVax Inc 36

Etubics Corp 36

Gemmus Pharma Inc 37

Genentech Inc 37

iBio Inc 38

ILiAD Biotechnologies LLC 38

Inovio Pharmaceuticals Inc 39

Johnson & Johnson 39

Kineta Inc 40

Kyowa Hakko Kirin Co Ltd 40

Lakewood-Amedex Inc 41

Medicago Inc 41

MedImmune LLC 42

Microbiotix Inc 42

Mucosis BV 43

NanoViricides Inc 43

NewLink Genetics Corp 44

Novavax Inc 44

OPKO Health Inc 45

PeptiDream Inc 45

Prommune Inc 46

Protein Sciences Corp 46

Recce Ltd 47

Sanofi Pasteur SA 47

Sarepta Therapeutics Inc 48

SK Chemicals Co Ltd 48

Takeda Pharmaceutical Company Ltd 49

TechnoVax Inc 49

Touchlight Genetics Ltd 50

Vaccibody AS 50

Vaxart Inc 51

Vironova AB 51

Visterra Inc 51

Zydus Cadila Healthcare Ltd 52

Influenza A Virus, H1N1 Subtype Infections Drug Profiles 53

AE-AI vaccine Drug Profile 53

AEA-35p Drug Profile 54

Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza A Virus, H1N1 Subtype Infections Drug Profile 55

Aspidasept Drug Profile 56

AV-5027 Drug Profile 57

AV-5080 Drug Profile 58

CC-42344 Drug Profile 59

cetylpyridinium chloride Drug Profile 60

CF-401 Drug Profile 61

CHOS-05 Drug Profile 62

CiFlu Drug Profile 63

diridavumab Drug Profile 65

EP-67 Drug Profile 67

ETBX-051 Drug Profile 68

Flu-v Drug Profile 69

Fluad (quadrivalent) Drug Profile 71

Fludase Drug Profile 72

FluGEM Drug Profile 75

Gamma-Flu Drug Profile 76

GP-1001 Drug Profile 77

GP-1681 Drug Profile 78

GREFLU/CAL Drug Profile 80

H1N1 [A/Aichi/2/68] vaccine Drug Profile 81

HB-36.6 Drug Profile 82

IN-1 Drug Profile 83

infectious disease vaccine Drug Profile 84

Influ-nRNA Drug Profile 85

influenza [strain A/H1N1] vaccine Drug Profile 86

influenza [strain A/H1N1] vaccine Drug Profile 88

influenza [strain A/H1N1] vaccine Drug Profile 89

influenza [strain H1N1] (virus like particle) vaccine Drug Profile 90

influenza [strain H1N1] vaccine Drug Profile 91

influenza [strain H1N1] vaccine Drug Profile 92

influenza [strain H1N1] vaccine Drug Profile 93

influenza [strain H1N1] vaccine Drug Profile 94

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine Drug Profile 95

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile 96

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile 97

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile 98

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine Drug Profile 99

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile 102

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine Drug Profile 103

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile 104

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine Drug Profile 105

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile 109

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile 110

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile 111

influenza [strains A/H1N1 + A/H3N2 + B] vaccine Drug Profile 112

influenza [strains A/H1N1 + A/H5N1] vaccine Drug Profile 113

influenza [strains A/H5N1 + A/H1N1] vaccine Drug Profile 114

influenza vaccine Drug Profile 115

INO-3510 Drug Profile 116

JNJ-3872 Drug Profile 118

KIN-1148 Drug Profile 121

KIN-1400 Drug Profile 123

LEAPS-H1N1-DC Drug Profile 125

MBX-2329 Drug Profile 126

MBX-2546 Drug Profile 127

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections Drug Profile 128

Nasovax Drug Profile 129

NBP-607 Drug Profile 131

NEO-8877 Drug Profile 132

Nucleozin Drug Profile 133

NVINF-1 Drug Profile 134

NVINF-2 Drug Profile 139

Oligonucleotide to Activate RIG-1 for Influenza A Virus H1N1 Infections Drug Profile 142

PD-001 Drug Profile 143

Peptides for Influenza Infections Drug Profile 144

pertussis [strain BPZE1] vaccine Drug Profile 145

PNSIA-28 Drug Profile 147

PNSIA-49 Drug Profile 148

radavirsen Drug Profile 149

RECCE-327 Drug Profile 151

RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection Drug Profile 153

Small Molecules for Influenza A Virus H1N1 and H5N1 Infections Drug Profile 154

Small Molecules for RSV and Influenza A Infections Drug Profile 155

Small Molecules to Block M2 Channel for Influenza Infections Drug Profile 156

Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections Drug Profile 157

Synthetic Peptides for Influenza, HSV and HIV Infections Drug Profile 158

TVX-002 Drug Profile 159

VH-244 Drug Profile 160

VIS-410 Drug Profile 161

VNFC-045 Drug Profile 164

VNFC-051 Drug Profile 165

VXAA-1.1 Drug Profile 166

WLBU-2 Drug Profile 168

Z-3G1 Drug Profile 169

Influenza A Virus, H1N1 Subtype Infections Dormant Projects 170

Influenza A Virus, H1N1 Subtype Infections Discontinued Products 173

Influenza A Virus, H1N1 Subtype Infections Product Development Milestones 174

Featured News & Press Releases 174

Appendix 186

Methodology 186

Coverage 186

Secondary Research 186

Primary Research 186

Expert Panel Validation 186

Contact Us 186

Disclaimer 187

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by AbbVie Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Akshaya Bio Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Altimmune Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Antigen Express Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by CEL-SCI Corp, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Cilian AG, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Cocrystal Pharma Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by ContraFect Corp, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Curevac AG, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by EpiVax Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Etubics Corp, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Gemmus Pharma Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Genentech Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by iBio Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by ILiAD Biotechnologies LLC, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Johnson & Johnson, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Kineta Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Lakewood-Amedex Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Medicago Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by MedImmune LLC, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Microbiotix Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Mucosis BV, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by NanoViricides Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by NewLink Genetics Corp, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Novavax Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by OPKO Health Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by PeptiDream Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Prommune Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Protein Sciences Corp, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Recce Ltd, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Sanofi Pasteur SA, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Sarepta Therapeutics Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by SK Chemicals Co Ltd, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by TechnoVax Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Touchlight Genetics Ltd, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Vaccibody AS, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Vaxart Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Vironova AB, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Visterra Inc, H1 2017

Influenza A Virus, H1N1 Subtype Infections Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Influenza A Virus, H1N1 Subtype Infections Dormant Projects, H1 2017

Influenza A Virus, H1N1 Subtype Infections Dormant Projects, H1 2017 (Contd..1), H1 2017

Influenza A Virus, H1N1 Subtype Infections Dormant Projects, H1 2017 (Contd..2), H1 2017

Influenza A Virus, H1N1 Subtype Infections Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports